Isoray Inc (ISR) 1.34 $ISR
IsoRay Could See Another Year Of Strong Gains
Kanak Kanti De - at Seeking Alpha - Tue Feb 03, 8:07PM CST
ISR: 1.34 (-0.06)
IsoRay Up 6.1%, Shares Break Through Resistance (ISR)
Comtex SmarTrend(R) - Tue Jan 20, 10:35AM CST
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 6.1% to $1.40 on 2.1x average daily volume. Thus far today, IsoRay has traded 944,000 shares, vs. average volume of 455,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's -0.6%) and outperformed the S&P 500 (6.1% to the S&P's -0.3%) during today's trading.
ISR: 1.34 (-0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 8:16AM CST
BCS: 15.77 (+0.12), ANV: 0.97 (-0.03), FRO: 2.96 (+0.07), BAK: 9.02 (+0.03), UNIS: 4.32 (+0.06), EXPR: 14.61 (+0.33), ASPS: 22.32 (+0.09), ISR: 1.34 (-0.06), AU: 12.33 (+0.36), MHR: 2.62 (+0.11), SAP: 69.09 (unch), CPL: 13.01 (+0.33), CYTR: 2.96 (+0.23), ARNA: 4.55 (+0.02), SWHC: 12.63 (-0.20), EHTH: 10.91 (-0.04), OUTR: 68.39 (+2.22)
UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Side Effects, Providing Men Improved Quality of Life
Marketwired - Tue Jan 20, 7:15AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that researchers at the University of Pittsburgh School of Medicine (UPMC) released peer-reviewed study results on Cesium-131 prostate cancer treatment, published in the December issue of Clinical Oncology. The study title is "Five Year Prostate-specific Antigen (PSA) Outcomes after Caesium Prostate Brachytherapy."
ISR: 1.34 (-0.06)
Hot Stock: IsoRay, Shares Drop 6.4% (ISR)
Comtex SmarTrend(R) - Fri Jan 16, 12:39PM CST
IsoRay (AMEX:ISR) is one of today's worst performing low-priced stocks, down 6.4% to $1.32 on 1.1x average daily volume. IsoRay has traded 531,000 shares thus far today, vs. average volume of 478,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's 0.3%) and underperformed the S&P 500 (-6.4% to the S&P's 0.6%) during today's trading.
ISR: 1.34 (-0.06)
IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence Providing Cutting Edge Cancer Treatments
Marketwired - Tue Jan 13, 7:15AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that Urologist Alexander Zyryanov M.D. Ph.D. and Radiation Oncologist Vasilii Oschepkov M.D. Ph.D. performed the first cases of Cesium-131 implantation for the treatment of prostate cancer on the European continent.
ISR: 1.34 (-0.06)
IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed on the NYSE Group
Marketwired - Mon Jan 12, 7:15AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that it ranked 5th highest in share price performance for the 2014 calendar year, with a 192% increase, among all 2,417 listed companies on the NYSE Group, which includes the NYSE and the NYSE MKT.
ISR: 1.34 (-0.06)
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer
Marketwired - Mon Dec 08, 7:02AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the world's first veterinary implant of a horse suffering from cancer utilizing IsoRay's Cesium-131 internal radiation (brachytherapy) cancer therapy.
ISR: 1.34 (-0.06)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 63.86 (-0.43), OPK: 13.80 (-0.28), ISR: 1.34 (-0.06), FOLD: 8.36 (-0.11), NSPH: 0.25 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 11:46AM CST
ANV: 0.97 (-0.03), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), SPRO: 1.51 (+0.01), EMES: 55.25 (+1.80), BDR: 1.71 (-0.02), SPHS: 0.44 (-0.01), ISR: 1.34 (-0.06), MILL: 2.07 (+0.09), EOX: 1.15 (unch), NADL: 2.10 (-0.02), ORPN: 7.17 (+0.04), CANF: 3.85 (+0.05), LAS: 0.69 (-0.01), MOLG: 2.46 (+0.03), PSIX: 51.65 (+1.82), GDP: 3.58 (+0.29), LRE: 8.46 (+0.24), NGD: 3.73 (-0.04), BDL: 34.03 (-0.42)
Stock to Watch: IsoRay Up 20.2% (ISR)
Comtex SmarTrend(R) - Mon Dec 01, 10:07AM CST
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 20.2% to $1.95 on 7.5x average daily volume. IsoRay has traded 6.5 million shares thus far today, vs. average volume of 859,000 shares per day. The stock has outperformed the Dow (20.2% to the Dow's -0.4%) and outperformed the S&P 500 (20.2% to the S&P's -0.9%) during today's trading.
ISR: 1.34 (-0.06)
IsoRay up premarket on brain cancer results
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:24AM CST
ISR: 1.34 (-0.06)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:13AM CST
KOG: 6.56 (-0.39), HK: 2.18 (-0.02), FRO: 2.96 (+0.07), ISR: 1.34 (-0.06), EOX: 1.15 (unch), DWA: 20.72 (+0.34), SSE: 5.23 (+0.22), CANF: 3.85 (+0.05), VNET: 19.05 (+0.95), GRPN: 7.97 (+0.51), POZN: 6.95 (+0.15), ONNN: 11.94 (+0.33), EXEL: 2.48 (+0.20)
IsoRay's Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed
ACCESSWIRE - Mon Dec 01, 7:19AM CST
World-Renowned Barrow Neurological Institute Releases Dramatic Brain Study Findings
ISR: 1.34 (-0.06)
Accuray CyberKnife M6 System Now Available in Manhattan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 5:05PM CST
Developer of radiation therapy systems, Accuray Inc (ARAY) recently announced that Winthrop University Hospital's NYCyberKnife Center has started treating patients with the company's CyberKnife M6 System.
VAR: 92.65 (+0.03), ISR: 1.34 (-0.06), ARAY: 8.00 (+0.24)
IsoRay net loss improves in FQ1
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:31AM CST
ISR: 1.34 (-0.06)
IsoRay EPS and revenue in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:02AM CST
ISR: 1.34 (-0.06)
IsoRay, Inc. Reports First Quarter Results
eTeligis - Mon Nov 17, 7:01AM CST
RICHLAND, WA, United States, via ETELIGIS INC., 11/17/2014 - - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of cancers of the prostate, brain, lung, head and neck and gynecological, announced its financial results for the quarter ended September 30, 2014.
ISR: 1.34 (-0.06)
IsoRay Celebrates 10 Year Success Story With the First Prostate Patient Treated With Cesium-131
ACCESSWIRE - Wed Oct 29, 7:31AM CDT
IsoRay Happenings Hot off the Press
ISR: 1.34 (-0.06)
IsoRay Could See Another Year Of Strong Gains
Kanak Kanti De - at Seeking Alpha - Tue Feb 03, 8:07PM CST
ISR: 1.34 (-0.06)
IsoRay Up 6.1%, Shares Break Through Resistance (ISR)
Comtex SmarTrend(R) - Tue Jan 20, 10:35AM CST
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 6.1% to $1.40 on 2.1x average daily volume. Thus far today, IsoRay has traded 944,000 shares, vs. average volume of 455,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's -0.6%) and outperformed the S&P 500 (6.1% to the S&P's -0.3%) during today's trading.
ISR: 1.34 (-0.06)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 8:16AM CST
BCS: 15.77 (+0.12), ANV: 0.97 (-0.03), FRO: 2.96 (+0.07), BAK: 9.02 (+0.03), UNIS: 4.32 (+0.06), EXPR: 14.61 (+0.33), ASPS: 22.32 (+0.09), ISR: 1.34 (-0.06), AU: 12.33 (+0.36), MHR: 2.62 (+0.11), SAP: 69.09 (unch), CPL: 13.01 (+0.33), CYTR: 2.96 (+0.23), ARNA: 4.55 (+0.02), SWHC: 12.63 (-0.20), EHTH: 10.91 (-0.04), OUTR: 68.39 (+2.22)
UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Side Effects, Providing Men Improved Quality of Life
Marketwired - Tue Jan 20, 7:15AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that researchers at the University of Pittsburgh School of Medicine (UPMC) released peer-reviewed study results on Cesium-131 prostate cancer treatment, published in the December issue of Clinical Oncology. The study title is "Five Year Prostate-specific Antigen (PSA) Outcomes after Caesium Prostate Brachytherapy."
ISR: 1.34 (-0.06)
Hot Stock: IsoRay, Shares Drop 6.4% (ISR)
Comtex SmarTrend(R) - Fri Jan 16, 12:39PM CST
IsoRay (AMEX:ISR) is one of today's worst performing low-priced stocks, down 6.4% to $1.32 on 1.1x average daily volume. IsoRay has traded 531,000 shares thus far today, vs. average volume of 478,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's 0.3%) and underperformed the S&P 500 (-6.4% to the S&P's 0.6%) during today's trading.
ISR: 1.34 (-0.06)
IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence Providing Cutting Edge Cancer Treatments
Marketwired - Tue Jan 13, 7:15AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that Urologist Alexander Zyryanov M.D. Ph.D. and Radiation Oncologist Vasilii Oschepkov M.D. Ph.D. performed the first cases of Cesium-131 implantation for the treatment of prostate cancer on the European continent.
ISR: 1.34 (-0.06)
IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed on the NYSE Group
Marketwired - Mon Jan 12, 7:15AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that it ranked 5th highest in share price performance for the 2014 calendar year, with a 192% increase, among all 2,417 listed companies on the NYSE Group, which includes the NYSE and the NYSE MKT.
ISR: 1.34 (-0.06)
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer
Marketwired - Mon Dec 08, 7:02AM CST
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the world's first veterinary implant of a horse suffering from cancer utilizing IsoRay's Cesium-131 internal radiation (brachytherapy) cancer therapy.
ISR: 1.34 (-0.06)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 63.86 (-0.43), OPK: 13.80 (-0.28), ISR: 1.34 (-0.06), FOLD: 8.36 (-0.11), NSPH: 0.25 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 11:46AM CST
ANV: 0.97 (-0.03), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), SPRO: 1.51 (+0.01), EMES: 55.25 (+1.80), BDR: 1.71 (-0.02), SPHS: 0.44 (-0.01), ISR: 1.34 (-0.06), MILL: 2.07 (+0.09), EOX: 1.15 (unch), NADL: 2.10 (-0.02), ORPN: 7.17 (+0.04), CANF: 3.85 (+0.05), LAS: 0.69 (-0.01), MOLG: 2.46 (+0.03), PSIX: 51.65 (+1.82), GDP: 3.58 (+0.29), LRE: 8.46 (+0.24), NGD: 3.73 (-0.04), BDL: 34.03 (-0.42)
Stock to Watch: IsoRay Up 20.2% (ISR)
Comtex SmarTrend(R) - Mon Dec 01, 10:07AM CST
IsoRay (AMEX:ISR) is one of today's best performing low-priced stocks, up 20.2% to $1.95 on 7.5x average daily volume. IsoRay has traded 6.5 million shares thus far today, vs. average volume of 859,000 shares per day. The stock has outperformed the Dow (20.2% to the Dow's -0.4%) and outperformed the S&P 500 (20.2% to the S&P's -0.9%) during today's trading.
ISR: 1.34 (-0.06)
IsoRay up premarket on brain cancer results
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:24AM CST
ISR: 1.34 (-0.06)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 8:13AM CST
KOG: 6.56 (-0.39), HK: 2.18 (-0.02), FRO: 2.96 (+0.07), ISR: 1.34 (-0.06), EOX: 1.15 (unch), DWA: 20.72 (+0.34), SSE: 5.23 (+0.22), CANF: 3.85 (+0.05), VNET: 19.05 (+0.95), GRPN: 7.97 (+0.51), POZN: 6.95 (+0.15), ONNN: 11.94 (+0.33), EXEL: 2.48 (+0.20)
IsoRay's Cesium-131 Therapy Stops Brain Cancers from Recurring in Treated Locations Where Previous Conventional Treatments Failed
ACCESSWIRE - Mon Dec 01, 7:19AM CST
World-Renowned Barrow Neurological Institute Releases Dramatic Brain Study Findings
ISR: 1.34 (-0.06)
Accuray CyberKnife M6 System Now Available in Manhattan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 5:05PM CST
Developer of radiation therapy systems, Accuray Inc (ARAY) recently announced that Winthrop University Hospital's NYCyberKnife Center has started treating patients with the company's CyberKnife M6 System.
VAR: 92.65 (+0.03), ISR: 1.34 (-0.06), ARAY: 8.00 (+0.24)
IsoRay net loss improves in FQ1
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:31AM CST
ISR: 1.34 (-0.06)
IsoRay EPS and revenue in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:02AM CST
ISR: 1.34 (-0.06)
IsoRay, Inc. Reports First Quarter Results
eTeligis - Mon Nov 17, 7:01AM CST
RICHLAND, WA, United States, via ETELIGIS INC., 11/17/2014 - - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of cancers of the prostate, brain, lung, head and neck and gynecological, announced its financial results for the quarter ended September 30, 2014.
ISR: 1.34 (-0.06)
IsoRay Celebrates 10 Year Success Story With the First Prostate Patient Treated With Cesium-131
ACCESSWIRE - Wed Oct 29, 7:31AM CDT
IsoRay Happenings Hot off the Press
ISR: 1.34 (-0.06)
